OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Diagnosis and therapeutic decision-making for the neutropenic patient	61
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	58
Your chemo is no good here: management of high-risk MCL	54
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	36
Neurological manifestations of MGUS	35
On the horizon: upcoming new agents for the management of ITP	33
Anticoagulation at the end of life: whether, when, and how to treat	33
Labor and delivery: DIC, HELLP, preeclampsia	30
Mastocytosis demystified	29
Recognizing, defining, and managing CAR-T hematologic toxicities	26
Inpatient recognition and management of HLH	26
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	26
Bispecific antibody therapies	25
Has PD-1 blockade changed the standard of care for cHL?	25
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	24
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	24
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	23
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	22
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	22
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	22
Divergent paths: management of early relapsed follicular lymphoma	21
Selecting initial therapy in CLL	21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	20
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	19
New approaches to tackle cytopenic myelofibrosis	19

Fitness and frailty in myeloma	18
MGCS: where do we stand today?	18
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	18
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	18
How to recognize and manage COVID-19-associated coagulopathy	18
Troubleshooting heparin resistance	17
How to diagnose and manage antiphospholipid syndrome	17
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	17
BV and beyond: how to incorporate novel agents into PTCL management	17
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	17
How to assess hemostasis in patients with severe liver disease	17
Optimizing outcomes in secondary AML	17
How to manage hemostasis in patients with liver disease during interventions	17
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	16
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	16
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	16
Hemophilia gene therapy: ushering in a new treatment paradigm?	16
Running interferon interference in treating PV/ET: meeting unmet needs	16
Management of TKI-resistant chronic phase CML	16
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	16
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	16
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	15
Hematology 2022—what is complete HLA match in 2022?	15
Consumptive coagulopathy in the ICU	15
Special considerations in GI bleeding in VWD patients	14
Management of limited-stage Hodgkin lymphoma	14
Atypical CML: diagnosis and treatment	13
How to manage bleeding disorders in aging patients needing surgery	13
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	13
What to use to treat AML: the role of emerging therapies	13
Demystifying autoimmune HIT: what it is, when to test, and how to treat	13
Managing therapy-associated neurotoxicity in children with ALL	13
Management of marginal zone lymphomas	13
Thrombosis questions from the inpatient wards	12
Approaches to management of HIT in complex scenarios, including cardiac surgery	12
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	12
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	12
Infectious complications and vaccines	12
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	12
CNS prophylaxis in aggressive B-cell lymphoma	11
Thrombocytopenia in pregnancy	11
Organ function indications and potential improvements following curative therapy for sickle cell disease	11
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	11
Alloimmunization and hyperhemolysis in sickle cell disease	11
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	11
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	11
Lower risk but high risk	11
When does a PNH clone have clinical significance?	11
Transplant in AML with measurable residual disease: proceed or defer?	11
Cytoreduction for ET and PV: who, what, when, and how?	10

How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	10
What makes a pediatric or young adult patient an appropriate transplant candidate?	10
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	10
Treatment of VTE in the thrombocytopenic cancer patient	10
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	10
Pegylated interferon: the who, why, and how	10
What is the ideal approach—doublet, triplet, or quadruplet(s)?	10
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	10
Next-generation therapy for lower-risk MDS	9
Ph− ALL: immunotherapy in upfront treatment	9
Managing side effects: guidance for use of immunotherapies in multiple myeloma	9
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	9
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	9
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	9
Novel therapies upon failure of HMA plus venetoclax	9
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	9
Clinical manifestations of telomere biology disorders in adults	9
Frontline treatment in CLL: the case for time-limited treatment	9
Whom should we treat with novel agents? Specific indications for specific and challenging populations	9
Diamond-Blackfan anemia	8
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	8
What else do I need to worry about when treating graft-versus-host disease?	8
Porphyria cutanea tarda: a unique iron-related disorder	8
IV iron formulations and use in adults	8
Treatment of older adult or frail patients with multiple myeloma	8
The role of stem cell transplant (auto and allo) in PTCL and CTCL	8
Approach to the patient with suspected hypereosinophilic syndrome	8
Sequencing bispecific antibodies and CAR T cells for FL	8
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	8
In 2022, which is preferred: haploidentical or cord transplant?	8
Should we use bisphosphonates to treat bone complications in sickle cell disease?	8
Warm autoimmune hemolytic anemia and the best treatment strategies	8
Barriers to accessing cellular therapy for patients receiving care in community practices	8